rs377767417
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 4P and 1B. PP3_StrongBP6
The NM_020975.6(RET):c.2371T>A(p.Tyr791Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000471 in 1,613,786 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y791F) has been classified as Likely benign.
Frequency
Consequence
NM_020975.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RET | NM_020975.6 | c.2371T>A | p.Tyr791Asn | missense_variant | Exon 13 of 20 | ENST00000355710.8 | NP_066124.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152212Hom.: 0 Cov.: 34
GnomAD3 exomes AF: 0.0000478 AC: 12AN: 251120Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135850
GnomAD4 exome AF: 0.0000479 AC: 70AN: 1461574Hom.: 0 Cov.: 34 AF XY: 0.0000481 AC XY: 35AN XY: 727072
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152212Hom.: 0 Cov.: 34 AF XY: 0.0000134 AC XY: 1AN XY: 74350
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia type 2A Uncertain:3Benign:1
- -
This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. -
- -
The RET c.2371T>A (p.Tyr791Asn) missense change has a maximum subpopulation frequency of 0.009% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a deleterious effect on protein function, but this prediction has not been confirmed by functional studies. This variant has been reported in individuals with c-cell hyperplasia, medullary thyroid cancer, and Hirschsprung disease, but has also been reported in unaffected individuals (PMID: 14557476, 17108762, 25425582, 28946813). In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -
Multiple endocrine neoplasia, type 2 Uncertain:2
This sequence change replaces tyrosine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 791 of the RET protein (p.Tyr791Asn). This variant is present in population databases (rs377767417, gnomAD 0.008%). This missense change has been observed in individual(s) with Hirschsprung disease and medullary thyroid cancer (PMID: 14557476, 17108762, 20013610, 23259706, 25425582, 26559152, 28946813). ClinVar contains an entry for this variant (Variation ID: 24939). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
This missense variant replaces tyrosine with asparagine at codon 791 of the RET protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in two individuals affected with medullary thyroid carcinoma (PMID: 23259706, 28946813), one of these individuals also carried a known pathogenic variant in the RET gene that could explain the observed phenotype (PMID: 23259706). This variant has also been reported in individuals affected with Hirschsprung disease (PMID: 17108762, 26559152) and several unaffected individuals (PMID: 14557476, 20013610, 25425582). This variant has been identified in 13/282514 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not specified Uncertain:1
DNA sequence analysis of the RET gene demonstrated a sequence change, c.2371T>A, in exon 13 that results in an amino acid change, p.Tyr791Asn. This sequence change has been described in the gnomAD database with a frequency of 0.009% in the non-Finnish European subpopulation (dbSNP rs377767417). The p.Tyr791Asn change affects a highly conserved amino acid residue located in a domain of the RET protein that is known to be functional. The p.Tyr791Asn substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change has been previously described in individuals with medullary thyroid cancer and Hirschsprung disease as well as individuals without disease (PMID: 25425582, 20013610, 17108762, 21479187, 26559152, 14557476, 23259706, 28946813). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Tyr791Asn change remains unknown at this time. -
Multiple endocrine neoplasia type 2B Uncertain:1
- -
Multiple endocrine neoplasia type 2A;C0025269:Multiple endocrine neoplasia type 2B;C0031511:Pheochromocytoma;C1275808:Congenital central hypoventilation;C1833921:Familial medullary thyroid carcinoma;C3888239:Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
Multiple endocrine neoplasia type 2A;C0025269:Multiple endocrine neoplasia type 2B;C0031511:Pheochromocytoma;C1833921:Familial medullary thyroid carcinoma;C3888239:Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
Hirschsprung disease, susceptibility to, 1 Uncertain:1
- -
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at